Molecular and Biological Mechanisms of Bone Metastasis

[1]  P. Johnston,et al.  The emerging role of CD44 in regulating skeletal micrometastasis. , 2006, Cancer letters.

[2]  O. Kollet,et al.  How do stem cells find their way home? , 2005, Blood.

[3]  Ivo Que,et al.  Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. , 2005, Cancer research.

[4]  M. Gillespie,et al.  Effects of parathyroid hormone on Wnt signaling pathway in bone , 2005, Journal of cellular biochemistry.

[5]  F. Saad,et al.  Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Ratajczak,et al.  Trafficking of Normal Stem Cells and Metastasis of Cancer Stem Cells Involve Similar Mechanisms: Pivotal Role of the SDF‐1–CXCR4 Axis , 2005, Stem cells.

[7]  J. Wysolmerski,et al.  TOPGAL Mice Show That the Canonical Wnt Signaling Pathway Is Active During Bone Development and Growth and Is Activated by Mechanical Loading In Vitro , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  K. Pienta,et al.  Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cells. , 2005, Cancer research.

[9]  G. Prindull.  Hypothesis: cell plasticity, linking embryonal stem cells to adult stem cell reservoirs and metastatic cancer cells? , 2005, Experimental hematology.

[10]  Xunbin Wei,et al.  In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment , 2005, Nature.

[11]  S. Rafii,et al.  A role for niches in hematopoietic cell development , 2005, Hematology.

[12]  D. Prockop,et al.  How Wnt Signaling Affects Bone Repair by Mesenchymal Stem Cells from the Bone Marrow , 2005, Annals of the New York Academy of Sciences.

[13]  K. Pienta,et al.  Bone turnover mediates preferential localization of prostate cancer in the skeleton. , 2005, Endocrinology.

[14]  R. Taichman.  Blood and bone: two tissues whose fates are intertwined to create the hematopoietic stem-cell niche. , 2005, Blood.

[15]  T. Yoneda,et al.  Crosstalk between cancer cells and bone microenvironment in bone metastasis. , 2005, Biochemical and biophysical research communications.

[16]  P. Clézardin,et al.  Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. , 2004, The Journal of clinical investigation.

[17]  J. Massagué,et al.  Platelets and metastasis revisited: a novel fatty link. , 2004, The Journal of clinical investigation.

[18]  Abraham Schneider,et al.  Skeletal Localization and Neutralization of the SDF‐1(CXCL12)/CXCR4 Axis Blocks Prostate Cancer Metastasis and Growth in Osseous Sites In Vivo , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  M. Walker,et al.  Analysis of Wnt Gene Expression in Prostate Cancer , 2004, Cancer Research.

[20]  Wenjun Guo,et al.  Integrin signalling during tumour progression , 2004, Nature Reviews Molecular Cell Biology.

[21]  A. Potti,et al.  Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. , 2004, Cancer.

[22]  D. Griggs,et al.  A small molecule antagonist of the αvβ3 integrin suppresses MDA-MB-435 skeletal metastasis , 2004, Clinical & Experimental Metastasis.

[23]  J. Kutok,et al.  Rolling of Human Bone-Metastatic Prostate Tumor Cells on Human Bone Marrow Endothelium under Shear Flow Is Mediated by E-Selectin , 2004, Cancer Research.

[24]  F. Balkwill.  Cancer and the chemokine network , 2004, Nature Reviews Cancer.

[25]  K. Michels,et al.  Hyperparathyroidism and subsequent incidence of breast cancer , 2004, International journal of cancer.

[26]  Paul J. Williams,et al.  Bone sialoprotein promotes bone metastasis of a non-bone-seeking clone of human breast cancer cells. , 2004, Anticancer research.

[27]  G. Roodman.  Mechanisms of bone metastasis. , 2004, Discovery medicine.

[28]  H. Adwan,et al.  Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells , 2004, Cancer Gene Therapy.

[29]  R. Taichman,et al.  Vascular Endothelial Growth Factor Contributes to the Prostate Cancer-Induced Osteoblast Differentiation Mediated by Bone Morphogenetic Protein , 2004, Cancer Research.

[30]  F. Zhan,et al.  The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. , 2003, The New England journal of medicine.

[31]  R. Coleman,et al.  Bone resorption predicts for skeletal complications in metastatic bone disease , 2003, British Journal of Cancer.

[32]  Hans Lilja,et al.  Biology of prostate-specific antigen. , 2003, Urology.

[33]  D. Scadden,et al.  Osteoblastic cells regulate the haematopoietic stem cell niche , 2003, Nature.

[34]  Haiyang Huang,et al.  Identification of the haematopoietic stem cell niche and control of the niche size , 2003, Nature.

[35]  Jae-Hyun Sung,et al.  BMP-2-induced Runx2 Expression Is Mediated by Dlx5, and TGF-β1 Opposes the BMP-2-induced Osteoblast Differentiation by Suppression of Dlx5 Expression* , 2003, Journal of Biological Chemistry.

[36]  J. Chirgwin,et al.  A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[37]  L. Suva,et al.  Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. , 2003, Bone.

[38]  K. Hruska,et al.  The Integrin {alpha}v{beta}3 and CD44 Regulate the Actions of Osteopontin on Osteoclast Motility , 2003, Calcified Tissue International.

[39]  J. Nelson,et al.  Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  K. Pienta,et al.  Stromal factors involved in prostate carcinoma metastasis to bone , 2003, Cancer.

[41]  H. Ryoo,et al.  The Protein Kinase C Pathway Plays a Central Role in the Fibroblast Growth Factor-stimulated Expression and Transactivation Activity of Runx2* , 2003, The Journal of Biological Chemistry.

[42]  I. Fidler,et al.  The organ microenvironment and cancer metastasis. , 2002, Differentiation; research in biological diversity.

[43]  P. Clézardin,et al.  Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. , 2002, Cancer research.

[44]  Jonathan R. Green.  Bisphosphonates in cancer therapy , 2002, Current opinion in oncology.

[45]  O. Kollet,et al.  The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2mnull mice , 2002, Leukemia.

[46]  L. Devy,et al.  Novel Antiangiogenic Effects of the Bisphosphonate Compound Zoledronic Acid , 2002, Journal of Pharmacology and Experimental Therapeutics.

[47]  Matthew R. Smith.  Osteoporosis during androgen deprivation therapy for prostate cancer. , 2002, Urology.

[48]  T. Powles,et al.  Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  N. Kieffer,et al.  Integrin αvβ3 expression confers on tumor cells a greater propensity to metastasize to bone , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[50]  C. Logothetis,et al.  Stem-cell origin of metastasis and heterogeneity in solid tumours. , 2002, The Lancet. Oncology.

[51]  I. Macdonald,et al.  Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.

[52]  G. Mundy.  Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities , 2002, Nature Reviews Cancer.

[53]  J. Winstanley,et al.  Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. , 2002, Cancer research.

[54]  Richard P Lifton,et al.  High bone density due to a mutation in LDL-receptor-related protein 5. , 2002, The New England journal of medicine.

[55]  S. Virtanen,et al.  Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. , 2002, Cancer research.

[56]  Ivan Lobov,et al.  Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor , 2002, The Journal of cell biology.

[57]  J. Brugge,et al.  Sensing the environment: a historical perspective on integrin signal transduction , 2002, Nature Cell Biology.

[58]  Evan T Keller,et al.  Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. , 2002, Cancer research.

[59]  T. Salo,et al.  Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines , 2002, Anti-cancer drugs.

[60]  J. Deng,et al.  The Novel Zinc Finger-Containing Transcription Factor Osterix Is Required for Osteoblast Differentiation and Bone Formation , 2002, Cell.

[61]  L. Trusolino,et al.  Osteopontin is an autocrine mediator of hepatocyte growth factor-induced invasive growth. , 2001, Cancer research.

[62]  Paul J. Williams,et al.  The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. , 2001, Cancer research.

[63]  L. Kanz,et al.  Transendothelial Migration of Hematopoietic Progenitor Cells , 2001 .

[64]  P. Garnero.  Markers of bone turnover in prostate cancer. , 2001, Cancer treatment reviews.

[65]  Elise C. Kohn,et al.  The microenvironment of the tumour–host interface , 2001, Nature.

[66]  S. Sone,et al.  Bone metastasis model with multiorgan dissemination of human small-cell lung cancer (SBC-5) cells in natural killer cell-depleted SCID mice. , 2001, Oncology research.

[67]  R. Coleman,et al.  The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases. , 2001, Seminars in oncology.

[68]  G. Naumov,et al.  Critical steps in hematogenous metastasis: an overview. , 2001, Surgical oncology clinics of North America.

[69]  M. Noda,et al.  Osteopontin Deficiency Reduces Experimental Tumor Cell Metastasis to Bone and Soft Tissues , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[70]  F. Singer,et al.  Bisphosphonate treatment inhibits the growth of prostate cancer cells. , 2001, Cancer research.

[71]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[72]  Lance A. Liotta,et al.  Cancer: An attractive force in metastasis , 2001, Nature.

[73]  J. Hopper,et al.  Parathyroid hormone-related protein production by breast cancers, improved survival, and reduced bone metastases. , 2001, Journal of the National Cancer Institute.

[74]  G. Laurie,et al.  Integrin expression and usage by prostate cancer cell lines on laminin substrata. , 2001, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[75]  J. Manivel,et al.  A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells. , 2001, The American journal of pathology.

[76]  P. Enzinger,et al.  Irinotecan in esophageal cancer. , 2000, Oncology.

[77]  J. Wozney,et al.  Runx2 Is a Common Target of Transforming Growth Factor β1 and Bone Morphogenetic Protein 2, and Cooperation between Runx2 and Smad5 Induces Osteoblast-Specific Gene Expression in the Pluripotent Mesenchymal Precursor Cell Line C2C12 , 2000, Molecular and Cellular Biology.

[78]  T. Nagasawa,et al.  A chemokine, SDF-1/PBSF, and its receptor, CXC chemokine receptor 4, as mediators of hematopoiesis. , 2000, International journal of hematology.

[79]  M. Glogauer,et al.  Intracellular osteopontin is an integral component of the CD44‐ERM complex involved in cell migration , 2000, Journal of cellular physiology.

[80]  P Delmas,et al.  Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. , 2000, Cancer research.

[81]  I. Macdonald,et al.  Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. , 2000, Cancer research.

[82]  G. Pirianov,et al.  Bisphosphonates induce apoptosis in human breast cancer cell lines , 2000, British Journal of Cancer.

[83]  C. Contag,et al.  Noninvasive assessment of tumor cell proliferation in animal models. , 1999, Neoplasia.

[84]  U. Studer,et al.  Osteopontin: possible role in prostate cancer progression. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[85]  I. Mazo,et al.  Adhesion and homing of blood‐borne cells in bone marrow microvessels , 1999, Journal of leukocyte biology.

[86]  T. Salo,et al.  MMP Inhibition and Downregulation by Bisphosphonates , 1999, Annals of the New York Academy of Sciences.

[87]  Napoleone Ferrara,et al.  VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation , 1999, Nature Medicine.

[88]  J. Nelson,et al.  New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. , 1999, Urology.

[89]  R Wieser,et al.  TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. , 1999, The Journal of clinical investigation.

[90]  D. Clohisy,et al.  Osteoclasts are required for bone tumors to grow and destroy bone , 1998, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[91]  H. Tsukahara,et al.  Endothelin subtype A receptor antagonist induces osteopenia in growing rats. , 1998, Metabolism: clinical and experimental.

[92]  K. Luzzi,et al.  Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. , 1998, The American journal of pathology.

[93]  D. Wallwiener,et al.  Reduction in new metastases in breast cancer with adjuvant clodronate treatment. , 1998, The New England journal of medicine.

[94]  L. Hofbauer,et al.  Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis. , 1998, European journal of endocrinology.

[95]  P. Clézardin.  Recent insights into the role of integrins in cancer metastasis , 1998, Cellular and Molecular Life Sciences CMLS.

[96]  N. Udagawa,et al.  Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. , 1998, Biochemical and biophysical research communications.

[97]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[98]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[99]  S. Mochizuki,et al.  Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. , 1998, Endocrinology.

[100]  M. Boranić,et al.  [[Long-term bone marrow culture]. , 1998, Arhiv za higijenu rada i toksikologiju.

[101]  R. Bell,et al.  Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  Stephen W. Byers,et al.  Serine Phosphorylation-regulated Ubiquitination and Degradation of β-Catenin* , 1997, The Journal of Biological Chemistry.

[103]  P. Delmas,et al.  Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. , 1997, Cancer research.

[104]  P. Croucher,et al.  Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti‐tumour activity , 1997, British journal of haematology.

[105]  C. Garlanda,et al.  Heterogeneity of endothelial cells. Specific markers. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[106]  S. Mundlos,et al.  Cbfa1, a Candidate Gene for Cleidocranial Dysplasia Syndrome, Is Essential for Osteoblast Differentiation and Bone Development , 1997, Cell.

[107]  G. Karsenty,et al.  Osf2/Cbfa1: A Transcriptional Activator of Osteoblast Differentiation , 1997, Cell.

[108]  Makoto Sato,et al.  Targeted Disruption of Cbfa1 Results in a Complete Lack of Bone Formation owing to Maturational Arrest of Osteoblasts , 1997, Cell.

[109]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[110]  G. Hortobagyi,et al.  Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. , 1996, The New England journal of medicine.

[111]  T. Powles,et al.  Clodronate decreases the frequency of skeletal metastases in women with breast cancer. , 1996, Bone.

[112]  B F Boyce,et al.  Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. , 1996, The Journal of clinical investigation.

[113]  J. Bonneterre,et al.  Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[114]  H. Lilja,et al.  Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. , 1996, Urology.

[115]  Zuxiong Chen,et al.  Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. , 1996, The Journal of urology.

[116]  H. Vloedgraven,et al.  Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. , 1996, The Journal of clinical investigation.

[117]  G. Rodan,et al.  Bisphosphonates: mechanisms of action , 1998, Endocrine reviews.

[118]  J. Hermans,et al.  Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients? , 1996, European journal of cancer.

[119]  M. Kovacs,et al.  Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. , 1996, The New England journal of medicine.

[120]  M. Glimcher,et al.  Receptor-Ligand Interaction Between CD44 and Osteopontin (Eta-1) , 1996, Science.

[121]  J. Nelson,et al.  Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate , 1995, Nature Medicine.

[122]  B F Boyce,et al.  Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. , 1995, Cancer research.

[123]  C. Hardy.  The Homing of Hematopoietic Stem Cells to the Bone Marrow , 1995, The American journal of the medical sciences.

[124]  D. Peehl,et al.  Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. , 1994, The Journal of endocrinology.

[125]  L. Bonewald,et al.  Effects of transforming growth factor β on bone nodule formation and expression of bone morphogenetic protein 2, osteocalcin, osteopontin, alkaline phosphatase, and type I collagen mRNA in long‐term cultures of fetal rat calvarial osteoblasts , 1994 .

[126]  L. Chung,et al.  Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. , 1994, Cancer research.

[127]  G. Stoica,et al.  Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[128]  T. Springer.  Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm , 1994, Cell.

[129]  B. Lilja,et al.  Quantitative Bone Scintigraphy in Prostatic Carcinoma - Long-Term Response to Treatment , 1993, Nuklearmedizin.

[130]  C. Manegold,et al.  Prophylactic treatment of skeletal metastases, tumor‐induced osteolysis, and hypercalcemia in rats with the bisphosphonate Cl2MBP , 1993, Cancer.

[131]  J. Hermans,et al.  Palliative pamidronate treatment in patients with bone metastases from breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[132]  M. Koutsilieris.  Osteoblastic metastasis in advanced prostate cancer. , 1993, Anticancer research.

[133]  R. Baggs,et al.  Effect of IL‐1 on experimental bone/bone‐marrow metastases , 1992, International journal of cancer.

[134]  M. Yacoub,et al.  Antigenic heterogeneity of vascular endothelium. , 1992, The American journal of pathology.

[135]  G. Powell,et al.  Localization of parathyroid hormone‐related protein mrna expression in breast cancer and metastatic lesions by in situ hybridization , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[136]  J. Hayman,et al.  Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. , 1991, Cancer research.

[137]  Martin Hofmann,et al.  A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells , 1991, Cell.

[138]  M. Tavassoli,et al.  Homing of Hemopoietic Progenitor Cells to the Marrow , 1991, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[139]  A. Mazar,et al.  An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. , 1990, Biochemical and biophysical research communications.

[140]  J. Hayman,et al.  Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer. , 1990, Cancer research.

[141]  T. Masaki,et al.  The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvariae. , 1990, Biochemical and biophysical research communications.

[142]  P. Ebeling,et al.  Immunohistochemical localization of parathyroid hormone‐related protein in parathyroid adenoma and hyperplasia , 1990, The Journal of pathology.

[143]  S. Kukreja,et al.  Development of skeletal metastasis by human prostate cancer in athymic nude mice , 1988, Clinical & Experimental Metastasis.

[144]  Sadao Kimura,et al.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells , 1988, Nature.

[145]  H. Marquardt,et al.  Complete amino acid sequence of human transforming growth factor type beta 2. , 1987, The Journal of biological chemistry.

[146]  G. Mundy,et al.  Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[147]  M. Klagsbrun,et al.  Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. , 1986, The Journal of biological chemistry.

[148]  J. Carter,et al.  Mechanisms of cancer metastasis to bone. , 1986, The Journal of bone and joint surgery. American volume.

[149]  M. Chapuy,et al.  Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma with special reference to osteomalacia , 1983, Cancer.

[150]  P. Gullino,et al.  Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. , 1975, Cancer research.

[151]  I. Fidler,et al.  Metastasis: Quantitative Analysis of Distribution and Fate of Tumor Emboli Labeled With 125I-5-Iodo-2′ -deoxyuridine , 1970 .

[152]  L. M. Franks.  The spread of prostatic carcinoma to the bones. , 1953, The Journal of pathology and bacteriology.

[153]  O. V. Batson.  THE FUNCTION OF THE VERTEBRAL VEINS AND THEIR ROLE IN THE SPREAD OF METASTASES , 1940, Annals of surgery.

[154]  S Paget,et al.  THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .

[155]  S. Kitazawa,et al.  The expression of parathyroid hormone-related protein in human breast cancer with skeletal metastases , 2005, Surgery Today.

[156]  C. Logothetis,et al.  Osteoblasts in prostate cancer metastasis to bone , 2005, Nature Reviews Cancer.

[157]  K. Pienta,et al.  Prostate Carcinoma Skeletal Metastases: Cross-talk between Tumor and Bone , 2004, Cancer and Metastasis Reviews.

[158]  P. Clézardin,et al.  In vitro and in vivo antitumor effects of bisphosphonates. , 2003, Current medicinal chemistry.

[159]  Mark L. Johnson,et al.  A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. , 2002, American journal of human genetics.

[160]  C. Blomqvist,et al.  Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[161]  I. Fidler,et al.  Critical determinants of cancer metastasis: rationale for therapy , 1999, Cancer Chemotherapy and Pharmacology.

[162]  C. E. van der Schoot,et al.  Constitutive expression of E-selectin and vascular cell adhesion molecule-1 on endothelial cells of hematopoietic tissues. , 1996, The American journal of pathology.

[163]  D. G. Osmond,et al.  Adhesion receptors on bone marrow stromal cells: in vivo expression of vascular cell adhesion molecule-1 by reticular cells and sinusoidal endothelium in normal and gamma-irradiated mice , 1996 .

[164]  N. Clarke,et al.  Osteoblast function and osteomalacia in metastatic prostate cancer. , 1993, European urology.

[165]  T. Powles,et al.  Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[166]  M. Müller,et al.  Protective effects of a prophylactic treatment with the bisphosphonate 3-amino-1-hydroxypropane-1,1-bisphosphonic acid on the development of tumor osteopathies in the rat: experimental studies with the Walker carcinosarcoma 256. , 1988, Oncology.

[167]  T. Dexter,et al.  Long-term marrow culture: an overview of techniques and experience. , 1984, Kroc Foundation series.

[168]  J. Bingham.  Letter: Lower oesophageal sphincter. , 1974, Lancet.